PureTech Health (GB:PRTC) has released an update.
PureTech Health plc, a clinical-stage biotherapeutics company, has successfully completed its $100 million Tender Offer, buying back 31,540,670 Ordinary Shares at a set price, with plans to cancel them. Shareholders participating in the Tender Offer are set to receive their proceeds through various payment methods by early July 2024. Following the buyback, PureTech Health’s total voting rights are now attached to 239,318,580 Ordinary Shares, with shares held in treasury not affecting this count.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
